Acticor Biotech SAS (ALACT.PA) Comparison with companies in other sectors?

Acticor Biotech SAS has a share price of 15.76M. You can analyze Acticor Biotech SAS (ALACT.PA) competitors across different market sectors through stock heatmaps.

What are ALACT.PA's NET and operating margins?

Acticor Biotech SAS (ALACT.PA) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does ALACT.PA's earnings per share (EPS) trend reflect its financial momentum?

Acticor Biotech SAS (ALACT.PA) EPS is -1.13 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Acticor Biotech SAS is -0.22, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Acticor Biotech SAS?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Acticor Biotech SAS like P/E which is -0.54, P/B which is -0.74, and PEG which is 0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Acticor Biotech SAS

ALACT.PA•EURONEXT

Healthcare

Biotechnology

€0.25

€0.00(0.00%)

Fundamental Analysis of Acticor Biotech SAS (ALACT.PA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-1.13

P/E Ratio

-0.22

ROE

1.38%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$3.94M

Shares OutstandingTotal number of shares issued

$15.76M

Book Value/ShareNet worth per share

$-0.34

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.13

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

137.95%

ROAReturn on total assets

-71.53%

ROCEReturn on capital employed

611.41%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.00

Cash/ShareCash and equivalents per share

$0.31

FCF YieldFree cash flow as percentage of market cap

-0.06%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ALACT.PAFinancial Ratios Analysis details for ALACT.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ALACT.PASector Benchmarking details for ALACT.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Acticor Biotech SAS Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Acticor Biotech SAS. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Acticor Biotech SAS's unique business strengths and challenges.

Key Financial Metrics for Acticor Biotech SAS

For Acticor Biotech SAS, essential financial indicators include EPS -1.13, PE -0.22, and ROE 1.38. These key ratios reveal insights into Acticor Biotech SAS's profitability, valuation, and operational health. Understanding these metrics enables you to compare Acticor Biotech SAS with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Acticor Biotech SAS

Metrics like Net Margin - and ROA -71.53% shed light on how well Acticor Biotech SAS is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Acticor Biotech SAS can sustain its operations and continue growing in the future.

Valuation and Market Position of Acticor Biotech SAS

Using ratios such as P/B Ratio -0.74 and PEG Ratio 0.00, investors can assess whether Acticor Biotech SAS is appropriately valued based on its financials and growth potential. These figures, combined with Acticor Biotech SAS's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Acticor Biotech SAS

Financial health indicators, such as Debt/Equity Ratio -1.37 and Cash Flow $-0.00, provide a snapshot of Acticor Biotech SAS's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Acticor Biotech SAS, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Acticor Biotech SAS

Investing in Acticor Biotech SAS based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Acticor Biotech SAS focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;